Axsome Therapeutics (AXSM) Consolidated Net Income: 2022-2025
Historic Consolidated Net Income for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$47.2 million.
- Axsome Therapeutics' Consolidated Net Income rose 26.89% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 26.20%. This contributed to the annual value of -$287.2 million for FY2024, which is 20.05% down from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Consolidated Net Income is -$47.2 million, which was up 1.47% from -$47.9 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Consolidated Net Income registered a high of -$11.2 million during Q1 2023, and its lowest value of -$98.6 million during Q4 2023.
- In the last 3 years, Axsome Therapeutics' Consolidated Net Income had a median value of -$64.6 million in 2024 and averaged -$61.9 million.
- In the last 5 years, Axsome Therapeutics' Consolidated Net Income skyrocketed by 71.64% in 2023 and then crashed by 508.27% in 2024.
- Over the past 4 years, Axsome Therapeutics' Consolidated Net Income (Quarterly) stood at -$61.2 million in 2022, then slumped by 61.06% to -$98.6 million in 2023, then climbed by 24.05% to -$74.9 million in 2024, then climbed by 26.89% to -$47.2 million in 2025.
- Its Consolidated Net Income was -$47.2 million in Q3 2025, compared to -$47.9 million in Q2 2025 and -$59.4 million in Q1 2025.